Video
Dr. Bosse on Rationale Behind Study of VEGF Plus Radium-223 in RCC
Author(s):
In Partnership With:
Dominick Bosse, MD, fellow, Dana-Farber Cancer Institute, discusses the rationale behind combining VEGF-targeted therapies and radium-223 dichloride (Xofigo) in metastatic renal cell carcinoma.
Dominick Bosse, MD, fellow, Dana-Farber Cancer Institute, discusses the rationale behind combining VEGF-targeted therapies and radium-223 dichloride (Xofigo) in metastatic renal cell carcinoma (mRCC).
In a study of patients with mRCC with bone metastases, pazopanib (Votrient) or sorafenib (Nexavar) was combined with radium-223. Primary endpoints were safety, efficacy and bone turnover markers.
Related Videos
Related Content
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
